ReviewChinese medical journal2017
Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
Review in Chinese medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Inhaler Devices as Potential Bacterial Reservoirs: A 30-Day Microbiota Analysis in Non-Cystic Fibrosis Bronchiectasis.Biomedicines · 2026Article
- Comparative analysis of the sputum microbiota in different COPD clinical states.Scientific reports · 2026Article
- Translational approaches in microbiome research: from functional mechanisms to next-generation therapeutics.Frontiers in microbiology · 2026Review
- The neonatal lung microbiome: a dynamic determinant of respiratory health, disease, and novel therapeutics.Frontiers in pediatrics · 2026Review
- Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: results from a prospective cohort study.Journal for immunotherapy of cancer · 2025Observational
- Comorbidity of lung cancer and chronic obstructive pulmonary disease: correlation and optimization of treatment strategies.Translational lung cancer research · 2025Review
- Article
- Host microbiome in tuberculosis: disease, treatment, and immunity perspectives.Frontiers in microbiology · 2023Review
- MicroRNA Let-7 Induces M2 Macrophage Polarization in COPD Emphysema Through the IL-6/STAT3 Pathway.International journal of chronic obstructive pulmonary disease · 2023Article
- Coinfection with influenza virus and non-typeableFrontiers in microbiology · 2023Article
- Exposure to particulate matter 2.5 leading to lung microbiome disorder and the alleviation effect ofInternational journal of occupational medicine and environmental health · 2022Article
- The impact of infection with COVID-19 on the respiratory microbiome: A narrative review.Virulence · 2022Review
- Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease.Frontiers in immunology · 2022Review
- Exposure to diesel exhaust particles results in altered lung microbial profiles, associated with increased reactive oxygen species/reactive nitrogen species and inflammation, in C57Bl/6 wildtype mice on a high-fat diet.Particle and fibre toxicology · 2021Article
- SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy.Cellular and molecular life sciences : CMLS · 2020Review
- High-throughput 16S rDNA sequencing of the pulmonary microbiome of rats with allergic asthma.Genes & diseases · 2020Article
- Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations.The Kaohsiung journal of medical sciences · 2020Article
- The Interplay Between Respiratory Microbiota and Innate Immunity in Flavor E-Cigarette Vaping Induced Lung Dysfunction.Frontiers in microbiology · 2020Review
- The lung microbiome: clinical and therapeutic implications.Internal and emergency medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe development of culture-independent techniques for microbiological analysis shows that bronchial tree is not sterile in either healthy or chronic obstructive pulmonary disease (COPD) individuals. With the advance of sequencing technologies, lung microbiome has become a new frontier for pulmonary disease research, and such advance has led to better understanding of the lung microbiome in COPD. This review aimed to summarize the recent advances in lung microbiome, its relationships with COPD, and the possible mechanisms that microbiome contributed to COPD pathogenesis. DATA SOURCES: Literature search was conducted using PubMed to collect all available studies concerning lung microbiome in COPD. The search terms were "microbiome" and "chronic obstructive pulmonary disease", or "microbiome" and "lung/pulmonary". STUDY SELECTION: The papers in English about lung microbiome or lung microbiome in COPD were selected, and the type of articles was not limited.
resultsThe lung is a complex microbial ecosystem; the microbiome in lung is a collection of viable and nonviable microbiota (bacteria, viruses, and fungi) residing in the bronchial tree and parenchymal tissues, which is important for health. The following types of respiratory samples are often used to detect the lung microbiome: sputum, bronchial aspirate, bronchoalveolar lavage, and bronchial mucosa. Disordered bacterial microbiome is participated in pathogenesis of COPD; there are also dynamic changes in microbiota during COPD exacerbations. Lung microbiome may contribute to the pathogenesis of COPD by manipulating inflammatory and/or immune process.
conclusionsNormal lung microbiome could be useful for prophylactic or therapeutic management in COPD, and the changes of lung microbiome could also serve as biomarkers for the evaluation of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.